Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers

SAN FRANCISCO & HOUSTON–(BUSINESS WIRE)– #KDM4–Tachyon Therapeutics, Inc. (“Tachyon” or “the Company”), a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today announced the closing of a financing that brings the Company’s total equity financing raises to $11.6 million and, together with a recently announced CIRM grant…